SARS-CoV-2 infection in cancer patients undergoing active treatment : analysis of clinical features and predictive factors for severe respiratory failure and death
Copyright © 2020 Elsevier Ltd. All rights reserved..
AIM: Previous studies have suggested a more frequent and severe course of novel coronavirus SARS-CoV-2 infection in cancer patients undergoing active oncologic treatment. Our aim was to describe the characteristics of the disease in this population and to determine predictive factors for poor outcome in terms of severe respiratory distress (acute respiratory distress syndrome [ARDS]) or death.
PATIENTS AND METHODS: Patients consecutively admitted for SARS-CoV-2 infection were prospectively collected, and retrospective statistical analysis was performed. Univariate and multivariate analyses were performed to assess potential factors for poor outcomes defined as ARDS or death.
RESULTS: Sixty-three patients were analysed, and 34 of them developed respiratory failure (70% as ARDS). Lymphocytes/mm3 (412 versus 686; p = 0.001), serum albumin (2.84 versus 3.1); lactate dehydrogenase (LDH) (670 versus 359; p < 0.001) and C-reactive protein (CRP) levels (25.8 versus 9.9; p < 0.001) discriminate those that developed respiratory failure. Mortality rate was 25%, significantly higher among ARDS, neutropenic patients (p = 0.01) and in those with bilateral infiltrates (44% versus 0%; p < 0.001). Multivariate logistic analyses model confirmed the predictive value of severe neutropenia (odds ratio [OR] 16.54; 95% confidence interval [CI] 1.43-190.9, p 0.025), bilateral infiltrates (OR 32.83, CI 95% 3.51-307, p 0.002) and tumour lung involvement (OR 4.34, CI 95% 1.2-14.95, p 0.02).
CONCLUSION: Cancer patients under active treatment admitted for SARS-CoV-2 infection have worse outcomes in terms of mortality and respiratory failure rates compared with COVID-19 global population. Lymphopenia, LDH, CRP and albumin discriminate illness severity, whereas neutropenia, bilateral infiltrates and tumour pulmonary involvement are predictive of higher mortality.
| Errataetall: |
CommentIn: Eur J Cancer. 2020 Oct;138:225-227. - PMID 32927375 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 135(2020) vom: 22. Aug., Seite 242-250 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yarza, Ramón [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019 novel coronavirus infection |
|---|
| Anmerkungen: |
Date Completed 28.07.2020 Date Revised 10.01.2021 published: Print-Electronic CommentIn: Eur J Cancer. 2020 Oct;138:225-227. - PMID 32927375 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2020.06.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311650325 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311650325 | ||
| 003 | DE-627 | ||
| 005 | 20231225142715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2020.06.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311650325 | ||
| 035 | |a (NLM)32586724 | ||
| 035 | |a (PII)S0959-8049(20)30313-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yarza, Ramón |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection in cancer patients undergoing active treatment |b analysis of clinical features and predictive factors for severe respiratory failure and death |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur J Cancer. 2020 Oct;138:225-227. - PMID 32927375 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a AIM: Previous studies have suggested a more frequent and severe course of novel coronavirus SARS-CoV-2 infection in cancer patients undergoing active oncologic treatment. Our aim was to describe the characteristics of the disease in this population and to determine predictive factors for poor outcome in terms of severe respiratory distress (acute respiratory distress syndrome [ARDS]) or death | ||
| 520 | |a PATIENTS AND METHODS: Patients consecutively admitted for SARS-CoV-2 infection were prospectively collected, and retrospective statistical analysis was performed. Univariate and multivariate analyses were performed to assess potential factors for poor outcomes defined as ARDS or death | ||
| 520 | |a RESULTS: Sixty-three patients were analysed, and 34 of them developed respiratory failure (70% as ARDS). Lymphocytes/mm3 (412 versus 686; p = 0.001), serum albumin (2.84 versus 3.1); lactate dehydrogenase (LDH) (670 versus 359; p < 0.001) and C-reactive protein (CRP) levels (25.8 versus 9.9; p < 0.001) discriminate those that developed respiratory failure. Mortality rate was 25%, significantly higher among ARDS, neutropenic patients (p = 0.01) and in those with bilateral infiltrates (44% versus 0%; p < 0.001). Multivariate logistic analyses model confirmed the predictive value of severe neutropenia (odds ratio [OR] 16.54; 95% confidence interval [CI] 1.43-190.9, p 0.025), bilateral infiltrates (OR 32.83, CI 95% 3.51-307, p 0.002) and tumour lung involvement (OR 4.34, CI 95% 1.2-14.95, p 0.02) | ||
| 520 | |a CONCLUSION: Cancer patients under active treatment admitted for SARS-CoV-2 infection have worse outcomes in terms of mortality and respiratory failure rates compared with COVID-19 global population. Lymphopenia, LDH, CRP and albumin discriminate illness severity, whereas neutropenia, bilateral infiltrates and tumour pulmonary involvement are predictive of higher mortality | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2019 novel coronavirus infection | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a COVID-19 virus disease | |
| 650 | 4 | |a Cáncer | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Predictive factors | |
| 650 | 4 | |a Respiratory distress syndrome | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Bover, Mateo |e verfasserin |4 aut | |
| 700 | 1 | |a Paredes, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a López-López, Flora |e verfasserin |4 aut | |
| 700 | 1 | |a Jara-Casas, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Castelo-Loureiro, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Baena, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Mazarico, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Folgueira, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Meléndez-Carmona, María Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Alhena |e verfasserin |4 aut | |
| 700 | 1 | |a Lumbreras, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Paz-Ares, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Pedroche, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Martín, Carlos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 135(2020) vom: 22. Aug., Seite 242-250 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2020 |g day:22 |g month:08 |g pages:242-250 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2020.06.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2020 |b 22 |c 08 |h 242-250 | ||